Endometrial cancer (EC) ranks as the second most prevalent gynecologic malignancy globally, with approximately 189,000 new ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.

Obesity is a growing concern worldwide, including in low- and middle-income countries (LMICs). Addressing this issue involves various strategies, including dietary and lifestyle changes, medical ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...

H.C. Wainwright reaffirmed a positive stance on Altimmune (NASDAQ:ALT) shares, maintaining a Buy rating and a $12.00 price target. Currently trading at $6.99 with a market capitalization of $497 ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.